





wherein each X is independently CR<sub>1</sub> or N, provided that if one X is N then the remaining X are CR<sub>1</sub>;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1, where the compound has the structure:



3. The compound of claim 2, wherein the compound has the structure:



wherein R<sub>2</sub> and R<sub>3</sub> are each independently hydrogen; -F; -Cl; -Br; -I; -CN; -(CH<sub>2</sub>)<sub>m</sub>OR<sub>5</sub>; -(CH<sub>2</sub>)<sub>m</sub>SR<sub>5</sub>; straight chained or branched C<sub>1</sub>-C<sub>7</sub> alkyl, monofluoroalkyl, polyfluoroalkyl; aryl or heteroaryl, wherein the aryl or heteroaryl may be substituted with one or more R<sub>1</sub>; or wherein R<sub>2</sub> and R<sub>3</sub> together can be -(CH<sub>2</sub>)<sub>p</sub>-;

wherein R<sub>4</sub> is straight chained or branched C<sub>1</sub>-C<sub>7</sub> alkyl, monofluoroalkyl or polyfluoroalkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, -N(R<sub>5</sub>)<sub>2</sub> or -(CH<sub>2</sub>)<sub>m</sub>OR<sub>5</sub>; and X is CH or N.

4. The compound of claim 3, wherein each R<sub>1</sub> is independently hydrogen; -F; -Cl; -Br; -I; -CN; -NO<sub>2</sub>; straight chained or branched C<sub>1</sub>-C<sub>7</sub> alkyl or polyfluoroalkyl; -(CH<sub>2</sub>)<sub>m</sub>OR<sub>5</sub>; -COR<sub>5</sub>; -CO<sub>2</sub>R<sub>5</sub>; -OCOR<sub>5</sub>; -CON(R<sub>5</sub>)<sub>2</sub>; -N(R<sub>5</sub>)COR<sub>5</sub> or -N(R<sub>5</sub>)CON(R<sub>5</sub>)<sub>2</sub>;

wherein R<sub>2</sub> and R<sub>3</sub> are each independently hydrogen; -F; -Cl; -Br; -I; -CN; -(CH<sub>2</sub>)<sub>m</sub>SR<sub>5</sub>; straight chained or branched C<sub>1</sub>-C<sub>7</sub> alkyl; aryl or heteroaryl, wherein the aryl or heteroaryl may be substituted with one or more R<sub>1</sub>; or wherein R<sub>2</sub> and R<sub>3</sub> together can be -(CH<sub>2</sub>)<sub>p</sub>-;

wherein R<sub>4</sub> is straight chained or branched C<sub>1</sub>-C<sub>7</sub> alkyl; C<sub>3</sub>-C<sub>6</sub> cycloalkyl; -N(R<sub>5</sub>)<sub>2</sub> or -(CH<sub>2</sub>)<sub>m</sub>OR<sub>5</sub>;

wherein each R<sub>5</sub> is independently hydrogen or straight chained or branched C<sub>1</sub>-C<sub>3</sub> alkyl, wherein the alkyl may be substituted with a phenyl;

wherein m is an integer 0 to 3 inclusive;


wherein n is an integer 1 to 3 inclusive;

wherein p is an integer from 2 to 5 inclusive;

wherein q is 0;

and X is CH.

5. The compound of claim 4, wherein the compound has the structure:




6. The compound of claim 5, wherein  $R_7$  is independently hydrogen or straight chained or branched  $C_1$ - $C_7$  alkyl; and  $R_4$  is straight chained or branched  $C_1$ - $C_7$  alkyl.

7. The compound of claim 6, wherein each  $R_1$  is independently hydrogen; -F; -Cl; -Br; -I or straight chained or branched  $C_1$ - $C_7$  alkyl; and  $R_2$  is hydrogen or straight chained or branched  $C_1$ - $C_7$  alkyl.

8. The compound of claim 7, wherein n is 2.

9. The compound of claim 8, wherein the compound is selected from the group consisting of:




10. The compound of claim 4, wherein  $R_2$  and  $R_3$  are independently hydrogen or straight chained or branched  $C_1$ - $C_7$  alkyl.

11. The compound of claim 10, wherein each  $R_5$  is independently hydrogen or straight chained or branched  $C_1$ - $C_3$  alkyl;  $R_7$  is independently hydrogen or straight chained or branched  $C_1$ - $C_7$  alkyl; and  $R_4$  is straight chained or branched  $C_1$ - $C_7$  alkyl.


12. The compound of claim 11, wherein each  $R_1$  is independently hydrogen; -F; -Cl; -Br; -I or straight chained or branched  $C_1$ - $C_7$  alkyl.

13. The compound of claim 12, wherein n is 2.

14. The compound of claim 13, wherein the compound is selected from the group consisting of:




15. The compound of claim 3, wherein the compound has the structure:



16. The compound of claim 4, wherein  $R_2$  and  $R_3$  together are  $-(CH_2)_p$ .

17. The compound of claim 2, wherein the compound has the structure:



wherein  $R_2$  is hydrogen or  $-OH$ .

18. The compound of claim 17, wherein  $R_3$  is phenyl substituted with one or more  $R_1$  moieties; and  $q = 0$ .

19. The compound of claim 18, wherein each  $R_5$  is independently hydrogen or straight chained or branched  $C_1$ - $C_3$  alkyl, wherein the alkyl may be substituted with a phenyl;  $R_7$  is independently hydrogen or straight chained or branched  $C_1$ - $C_7$  alkyl; and  $R_4$  is straight chained or branched  $C_1$ - $C_7$  alkyl.

20. The compound of claim 19, wherein each  $R_1$  is independently hydrogen;  $-F$ ;  $-Cl$ ;  $-Br$ ;  $-I$  or straight chained or branched  $C_1$ - $C_7$  alkyl.


21. The compound of claim 20, wherein  $n$  is 2.

22. The compound of claim 21, wherein  $X$  is  $N$ .


23. The compound of claim 21, wherein  $X$  is  $CR_1$ .

24. The compound of claim 23, wherein  $R_2$  is OH.

25. The compound of claim 24, wherein the compound is selected from the group consisting of:



26. The compound of claim 2, wherein the compound has the structure:




27. The compound of claim 26, wherein  $R_3$  is phenyl substituted with one or more  $R_1$  moieties; and  $q = 0$ .

28. The compound of claim 27, wherein  $R_5$  and  $R_7$  are independently hydrogen or straight chained or branched  $C_1$ - $C_7$  alkyl; and  $R_4$  is straight chained or branched  $C_1$ - $C_7$  alkyl.

29. The compound of claim 28, wherein  $R_2$  is hydrogen or -OH.

30. The compound of claim 29, wherein the compound has the structure:



31. The compound of claim 1, wherein the compound is enantiomerically pure.

32. The compound of claim 1, wherein the compound is diastereomerically pure.

33. A pharmaceutical composition that comprises a therapeutically effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier.

34. A pharmaceutical composition made by admixing a compound of claim 1 and a pharmaceutically acceptable carrier.

35. A process for making a pharmaceutical composition comprising admixing a compound of claim 1 and a pharmaceutically acceptable carrier.

36. A method of treating a subject suffering from an affective disorder selected from the group consisting of depression, major depression, bipolar disorder, agoraphobia, specific phobia, social phobia, obsessive-compulsive disorder, post-traumatic stress disorder, acute stress disorder and anxiety, comprising administering to the subject a therapeutically effective amount of the compound of claim 1.

37. A method of treating a subject suffering from a urinary disorder selected from the group consisting of urinary incontinence, urge incontinence, urinary frequency, urinary urgency, nocturia or enuresis comprising administering to the subject a therapeutically effective amount of the compound of claim 1.

38. A method of treating a subject suffering from an eating disorder selected from the group consisting of obesity, bulimia, bulimia nervosa or anorexia nervosa comprising administering to the subject a therapeutically effective amount of the compound of claim 1.